Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Thomas W. J
Electroceuticals for Paralympic Athletes: A Fair Play and Classification Concern? - Sports Medicine
Abstract Electroceuticals such as brain computer interfaces and spinal cord stimulation (SCS) represent transformative strategies for neuromodulation. Research has demonstrated that SCS can ameliorate motor and autonomic cardiovascular dysfunctions, particularly in individuals with spinal cord injury (SCI). Notably, SCS has been shown to augment aerobic exercise performance.
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study | Arthritis Research & Therapy | Full Text
Study design Full details of the study design have been published previously [29]. Briefly, AVERT-2 (NCT02504268) was a phase IIIb, 132-week, randomized, double-blind, placebo-controlled study of MTX-naive, anti-citrullinated protein antibody (ACPA)-positive patients with active, early RA.
Author Correction: Glycobiology of rheumatic diseases
Nature Reviews Rheumatology, Apr 2023 This is a preview of a remote PDF: https://www.nature.com/articles/s41584-023-00922-8.pdf Kissel, Theresa, Toes, René E. M., Huizinga, Thomas W. J., Wuhrer, Manfred. , Nature Reviews Rheumatology, DOI: 10.1038/s41584-023-00922-8
Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept | Arthritis Research & Therapy | Full Text
Abstract Background Drug-free remission is a desirable goal in rheumatoid arthritis (RA) for both patients and clinicians. The aim of this post hoc analysis was to investigate whether clinical and magnetic resonance imaging (MRI) variables in patients with early RA who achieved remission with methotrexate and/or abatacept at 12 months could predict disease flare following treatment withdrawal.
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study (pdf) | Paperity
Arthritis Research & Therapy, Apr 2023 This is a preview of a remote PDF: https://arthritis-research.biomedcentral.com/counter/pdf/10.1186/s13075-023-03038-2 Emery, Paul, Tanaka, Yoshiya, Bykerk, Vivian P., Bingham, Clifton O., Huizinga, Thomas W. J., Citera, Gustavo, Huang, Kuan-Hsiang Gary, Wu, Chun, Connolly, Sean E., Elbez, Yedid, Wong, Robert, Lozenski, Karissa, Fleischmann, Roy. , Arthritis Research & Therapy, 2023, pp. 1-13, Volume 25, Issue 1, DOI: 10.1186/s13075-023-03038-2
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Thomas W.
Contact Thomas W., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack